home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

BRUNO STRIGINI
Group Vice President and President, EUCAN Region II
Global Pharmaceutical Business

Schering-Plough Corporation
Kenilworth, New Jersey

Bruno Strigini is group vice presidentand president, EUCAN region II, for the Global Pharmaceutical Business of Schering-Plough Corporation's Europe-based regional organization (EUCAN). This region encompasses Austria, Belgium, Greece, the Netherlands, Portugal, Switzerland, Central & Eastern Europe, the Middle East and Africa.

With an extensive background in the international pharmaceutical industry, Strigini came to Schering-Plough from UCB-Celltech, Brussels, Belgium, where he served as president for international operations. Before that position, Strigini was in charge of UCB Japan/Asia-Pacific and was head of global marketing, business development and strategy. Strigini's earlier career included positions at SmithKline Beecham in the U.K. and New Zealand and the Fournier Group in France, the UK, and Spain.

Strigini holds a master's degree in microbiology from Heriot-Watt University in Edinburgh, Scotland, a doctorate of pharmacy from the University of Montpellier, France, and an M.B.A. from IMD, Lausanne, Switzerland.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough